Biote Stock Price, News & Analysis

biote Corp. (Nasdaq: BTMD) announced that it will release its first quarter financial results on May 9, 2023, after market close. A conference call to discuss these results is set for May 10, 2023, at 8:30 a.m. ET. Investors can access the call via phone or a live webcast. Biote specializes in personalized hormone optimization therapies aimed at transforming healthy aging. The company operates within an $8 billion global market, focusing on training practitioners to address hormone-related aging conditions. The press release also includes forward-looking statements highlighting various risks, such as regulatory pressures and competition. Investors are encouraged to review Biote's Annual Report and other SEC filings for further details on risks and uncertainties.

Biote (NASDAQ: BTMD) announced the appointment of John Denne as General Manager of its Men’s Health Division, a move aimed at expanding the company's footprint in the male hormone replacement therapy market. Denne brings over 30 years of healthcare experience, having previously driven commercial success at Endo International in Men’s Health. Terry Weber, CEO of Biote, expressed excitement over Denne’s track record in brand recognition and sustainable growth. Denne echoed these sentiments, highlighting the significant opportunity in hormone replacement therapy for men, which remains largely unmet. Biote operates in a $7 billion global market focused on hormone optimization therapies, and this leadership change is anticipated to accelerate their growth initiatives.

Biote (NASDAQ: BTMD) announced strong financial results for Q4 and the full year 2022, achieving record revenue of $165.0 million and a 24.6% increase in Adjusted EBITDA to $50.1 million. The Q4 revenue rose 18.5% to $44.5 million, supported by a 40% increase in Adjusted EBITDA to $13.1 million. Despite a net income of $1.3 million, the company reported an operating loss of $60.7 million due to substantial stock compensation and transaction-related expenses. For 2023, Biote anticipates revenue between $190-$200 million and Adjusted EBITDA of $56-$60 million, reflecting a continued focus on growth and market expansion.

Biote announced a successful case study involving a 54-year-old male patient with osteoporosis who achieved significant recovery after one year of testosterone pellet therapy. The therapy resulted in a notable increase in testosterone levels and improved bone density, enabling the patient to resume triathlon training. The findings, published in The Aging Male journal, highlight the potential benefits of sustained testosterone levels in treating osteoporosis and emphasize the need for more standardized treatment protocols. An estimated 10 million Americans over 50 have osteoporosis, underlining the impact of these findings on public health.

Biote Corp. (Nasdaq: BTMD), a leader in personalized hormone therapy, will participate in the 35th Annual Roth Conference from March 12-14, 2023, in Dana Point, CA. CEO Terry Weber and CFO Samar Kamdar will present on March 14 at 10:00 a.m. local time, alongside Chairman Marc Beer in investor meetings. Biote focuses on hormone optimization therapies, addressing a $7 billion global market, providing affordable solutions for symptoms related to hormone-related aging. Forward-looking statements in the release highlight potential risks and uncertainties regarding future performance.

Biote Corp. (NASDAQ: BTMD) announced it will release its fourth quarter and full year financial results on March 28, 2023, after market close. A conference call is scheduled for March 29, 2023, at 8:30 a.m. ET. Biote specializes in preventive health care through personalized hormone therapy and operates in a $7 billion global market for hormone-related aging conditions. Biote trains medical providers to identify and treat these conditions, aiming for enhanced patient outcomes and clinic success.

biote Corp. (NASDAQ: BTMD) has completed its underwritten public offering of 8.5 million shares of Class A common stock at $3.00 per share, including the exercise of underwriters’ option for 1.1 million shares. Notably, Biote is not receiving any proceeds from this offering, which was previously registered with the SEC. The offering is part of a strategic initiative to enhance market presence in the $7 billion hormone optimization market, delivering personalized health care through certified medical providers.

biote Corp. (NASDAQ: BTMD) announced a public offering of 7,391,305 shares of its Class A common stock at $3.00 per share, totaling approximately $22.17 million. The offering, set to close around January 9, 2023, involves selling stockholders, and the company will not receive proceeds from this transaction. Underwriters have a 30-day option to purchase an additional 1,108,695 shares. The registration statement was effective as of January 4, 2023, and the preliminary prospectus is available on the SEC's website.

Biote Corp. (Nasdaq: BTMD) has announced its participation in the Jefferies London Healthcare Conference from November 15-17, 2022. CEO Terry Weber will present on November 15, 2022, at 12:20 p.m. local time, followed by a Q&A session with CFO Samar Kamdar. A live audio webcast of the presentation will be available here. Biote specializes in personalized hormone therapy, targeting a $7 billion market in preventive healthcare.